March 17, 2020

Trans Chromosomics, Inc.

Trans Chromosomics concludes a research agreement with Precision Antibody with respect to development of therapeutic monoclonal antibody drug against a new type of coronavirus (COVID-19) using fully human antibody-producing mice

We are pleased to announce that, Trans Chromosomics, Inc. (TC), and Precision Antibody (PA), have entered into an agreement to collaborate on the development of a fully human monoclonal antibody for the treatment of COVID-19. TC provides fully human antibody-producing mice, and PA produces antibodies using unique antibody acquisition technology.

For the production of COVID-19 therapeutic antibodies, TC aims to obtain unique antibodies, through a joint research collaboration with the National Institute of Infectious Diseases (NIID) and Tottori University, detail of which is available on our website.

We have also partnered with PA, which has a long track record in antibody acquisition technology with many global large pharma and public organizations such as the National Institutes of Health (NIH), to develop therapeutic antibodies against COVID-19. In response to the internationally urgent issue of production of, we hope to be able to achieve the development of the best therapeutic antibodies in the shortest time by “Competitive Collaboration”, using various methods in parallel.

・Trans Chromosomics, Inc.

Headquarter in Yonago City, Tottori Pref., Japan

Mitsuo Oshimura, professor emeritus of Tottori University (CEO of TC Company), established TC in 2014 as a venture company from Tottori University. TC is a world leader in artificial chromosome engineering technology. This technology was developed throughout Oshimura's research for over 40 years. Fully human antibody-producing mice which are of the highest quality in the world were also created using artificial chromosome engineering technology. TC has already provided NIH with fully human antibody-producing mice under joint research.

・Precision Antibody™

Headquarter in Columbia, Maryland, U.S.A

PA—a wholly-owned service division of A&G Pharmaceutical, Inc. in the U.S.A— was established in 2000, and has become recognized as a leader in contract antibody development company. PA is recognized for their accelerated delivery of monoclonal antibodies that work in the intended applications using state-of-the-art technology (40-60 days with a success rate exceeding 90%). PA has developed more than 10,000 novels, customized antibodies for pharmaceutical and biotechnology companies as well as federal and academic research laboratories.